Correct answer = B.
<p>  Amiodarone pulmonary toxicity most
     commonly presents subacutely with symptoms of dyspnea on
     exertion, nonproductive cough, fever, malaise, and weight loss
     progressing over a 2 to 3 month period.  Pleuritic chest pain
     has only rarely been reported.  DLCO is universally decreased
     in patients with amiodarone pulmonary toxicity;, however, the
     significance of an isolated decrease in DLCO is unclear and
     many authorities recommend continued treatment, with close
     observation, unless there is also a decrease in TLC.  Luckily,
     discontinuation of amiodarone results in complete reversal of
     the pulmonary abnormalities in most patients.  There is no
     clear evidence that steroids are beneficial in either treating
     or preventing amiodarone pulmonary toxicity.